SCHEMBL20695128

SCHEMBL20695128

O=C1CCC2(CN(C(=O)c3cc(-c4ccccc4)cs3)C2)N1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 1/20 0.41
▸ MMP12 P39900 5/20 0.36
▸ USP30 Q70CQ3 1/20 0.35
▸ ALAD P13716 2/20 0.35
▸ MGLL Q99685 3/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ SCD5 Q86SK9 1/20 0.34
▸ BRD4 O60885 1/20 0.33
▸ ITGA2B P08514 1/20 0.32
▸ MMP13 P45452 2/20 0.32
▸ MMP3 P08254 1/20 0.32
▸ MMP9 P14780 1/20 0.32
▸ MMP8 P22894 1/20 0.32
▸ USP2 O75604 2/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ CYP3A4 P08684 2/20 0.32
▸ HPGD P15428 2/20 0.32
▸ HSD17B10 Q99714 2/20 0.32
▸ PDE4B Q07343 1/20 0.32
▸ MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20695443 0.81 HTR3E (0.38) MGLLBRD4USP2ALDH1A1CYP3A4
SCHEMBL20695210 0.80 MAPK1 (0.50) L3MBTL1USP2ALDH1A1CYP3A4HPGD
SCHEMBL20695092 0.80 RAB9A (0.43) HDAC6ALDH1A1HPGDMEN1KMT2A
SCHEMBL20695340 0.80 BRD4 (0.50) MGLLBRD4USP2ALDH1A1CYP3A4
SCHEMBL20695447 0.78 MGLL (0.39) MGLLSCD5BRD4USP2ALDH1A1
SCHEMBL20695190 0.76 GHSR (0.43) MGLLBRD4USP2ALDH1A1CYP3A4
SCHEMBL20695299 0.76 GHSR (0.44) MGLLBRD4USP2ALDH1A1HPGD
SCHEMBL20695496 0.76 MGLL (0.39) HDAC6MGLLBRD4PDE4B
SCHEMBL20695396 0.76 PDCD1LG2 (0.37) MGLLBRD4USP2ALDH1A1CYP3A4
SCHEMBL20695172 0.75 HRH4 (0.52) HDAC6L3MBTL1ALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10610520-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-04-07 — — US disclosed
US-20190125728-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-05-02 — — US disclosed
US-20190125728-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-05-02 — — US disclosed
EP-3438109-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2019-02-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190125728-A1 HETEROCYCLIC COMPOUND MAG, HTT, ACHE HDAC6 91/4885MMP12 421/4885USP30 4327/4885
US-10610520-B2 Heterocyclic compound MAG, HTT, ACHE HDAC6 91/4885MMP12 421/4885USP30 4327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback